Evidence map›Paper›PMID 38922889›Full record

ArticlePhotochemistry and photobiology

Red light-activated depletion of drug-refractory glioblastoma stem cells and chemosensitization of an acquired-resistant mesenchymal phenotype.

Bryan Q Spring, Kohei Watanabe, Megumi Ichikawa, Srivalleesha Mallidi, Tatsuyuki Matsudaira, Dmitriy Timerman, Joseph W R Swain, Zhiming Mai, Hiroaki Wakimoto, Tayyaba Hasan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Photochemistry and photobiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bryan Q SpringWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0001-7332-7707
Kohei WatanabeWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Megumi IchikawaWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Srivalleesha MallidiWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0003-1547-1764
Tatsuyuki MatsudairaWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Dmitriy TimermanWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Joseph W R SwainWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Zhiming MaiWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Hiroaki WakimotoBrain Tumor Research Center and Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Tayyaba HasanWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Funding

Targeted Photoactivable Nanocells: Image-based Drug Delivery and Dosimetry in GBMR01CA156177 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA, POGUE, BRIAN WILLIAM · 2011 to 2015
$2.5M
Online monitoring and image-guided treatment of chemoresistant micrometastasesK22CA181611 · NCI · NORTHEASTERN UNIVERSITY · PI SPRING, BRYAN QUILTY · 2015 to 2017
$559k
Glioblastoma PDT Design: Nanoagent Uptake and Tumor Oxygenation based dosimetryF32CA165881 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MALLIDI, SRIVALLEESHA · 2012 to 2014
$163k
Canon Medical Systems USAMassachusetts General HospitalNCI NIH HHS F32 CA165881NCI NIH HHS K22 CA181611NCI NIH HHS R01 CA156177
6 · The paper itself

Abstract

Glioblastoma stem cells (GSCs) are potent tumor initiators resistant to radiochemotherapy, and this subpopulation is hypothesized to re-populate the tumor milieu due to selection following conventional therapies. Here, we show that 5-aminolevulinic acid (ALA) treatment-a pro-fluorophore used for fluorescence-guided cancer surgery-leads to elevated levels of fluorophore conversion in patient-derived GSC cultures, and subsequent red light-activation induces apoptosis in both intrinsically temozolomide chemotherapy-sensitive and -resistant GSC phenotypes. Red light irradiation of ALA-treated cultures also exhibits the ability to target mesenchymal GSCs (Mes-GSCs) with induced temozolomide resistance. Furthermore, sub-lethal light doses restore Mes-GSC sensitivity to temozolomide, abrogating GSC-acquired chemoresistance. These results suggest that ALA is not only useful for fluorescence-guided glioblastoma tumor resection, but that it also facilitates a GSC drug-resistance agnostic, red light-activated modality to mop up the surgical margins and prime subsequent chemotherapy.

Indexed as

Drug Resistance, NeoplasmGlioblastomaLightNeoplastic Stem CellsAminolevulinic AcidApoptosisBrain NeoplasmsCell Line, TumorHumansPhenotypeRed LightTemozolomideAminolevulinic AcidTemozolomidecancer stem cellschemosensitizationdrug‐resistanceglioblastomamesenchymalphotodynamic therapy

Identifiers

PMID38922889
PMCPMC11664018

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.